These include activating mutations in epidermal growth factor receptor (EGFR) and B-rapidly growing fibrosarcoma (BRAF) or anaplastic lymphoma kinase (ALK) fusions and c-ros oncogene 1(ROS1) receptor tyrosine kinase fusions. Here, EGFR is linked to fibrosarcoma.